Generation Bio Co. Financials
This page shows Generation Bio Co. (GBIO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Generation Bio remains a development-stage company where research spending and cash burn still outweigh its early commercial revenue base.
FY2024 revenue reached$19.9M , but operating cash burn still ran at-$88.6M . With R&D spending at$61.3M , the added top line has not changed the core mechanic: liquid assets, not customers, are still funding development.
Current assets of
The company did reduce spend, with R&D down from
Financial Health Signals
Scored against operating companies for FY2024. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Generation Bio Co.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Generation Bio Co. has an operating margin of -715.8%, meaning the company retains $-716 of operating profit per $100 of revenue. This below-average margin results in a low score of 16/100, suggesting thin profitability after operating expenses. This is up from -2346.9% the prior year.
Generation Bio Co.'s revenue surged 236.9% year-over-year to $19.9M, reflecting rapid business expansion. This strong growth earns a score of 99/100.
Generation Bio Co. has a moderate D/E ratio of 1.68. This balance of debt and equity financing earns a leverage score of 34/100.
With a current ratio of 5.50, Generation Bio Co. holds $5.50 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 91/100.
While Generation Bio Co. generated -$88.6M in operating cash flow, capex of $2.4M consumed most of it, leaving -$91.0M in free cash flow. This results in a low score of 2/100, reflecting heavy capital investment rather than weak cash generation.
Generation Bio Co. generates a -152.7% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 26/100. This is down from -62.3% the prior year.
Generation Bio Co. scores -5.24, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($36.0M) relative to total liabilities ($145.0M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Generation Bio Co. passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Generation Bio Co. generates $0.67 in operating cash flow (-$88.6M OCF vs -$131.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Generation Bio Co. generated $19.9M in revenue in fiscal year 2024. This represents an increase of 236.9% from the prior year.
Generation Bio Co.'s EBITDA was -$137.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 3.1% from the prior year.
Generation Bio Co. reported -$131.7M in net income in fiscal year 2024. This represents a decrease of 4.0% from the prior year.
Generation Bio Co. earned $-1.98 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 1.0% from the prior year.
Cash & Balance Sheet
Generation Bio Co. generated -$91.0M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 51.2% from the prior year.
Generation Bio Co. held $76.3M in cash against $0 in long-term debt as of fiscal year 2024.
Generation Bio Co. had 7M shares outstanding in fiscal year 2024. This represents a decrease of 89.9% from the prior year.
Margins & Returns
Generation Bio Co.'s operating margin was -715.8% in fiscal year 2024, reflecting core business profitability. This is up 1631.1 percentage points from the prior year.
Generation Bio Co.'s net profit margin was -661.9% in fiscal year 2024, showing the share of revenue converted to profit. This is up 1482.6 percentage points from the prior year.
Generation Bio Co.'s ROE was -152.7% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 90.4 percentage points from the prior year.
Capital Allocation
Generation Bio Co. invested $61.3M in research and development in fiscal year 2024. This represents a decrease of 34.5% from the prior year.
Generation Bio Co. invested $2.4M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 67.5% from the prior year.
GBIO Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.6M+108.4% | $765K-91.2% | $8.7M+108.3% | $4.2M-44.6% | $7.6M+84.6% | $4.1M+0.8% | $4.1M | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $21.6M+39.6% | $15.5M+0.9% | $15.4M-0.9% | $15.5M+2.7% | $15.1M-7.9% | $16.4M+14.3% | $14.3M | N/A |
| SG&A Expenses | $12.2M+58.6% | $7.7M-13.2% | $8.8M+2.1% | $8.7M-5.7% | $9.2M-3.5% | $9.5M-8.8% | $10.4M | N/A |
| Operating Income | -$6.7M+70.7% | -$22.9M-38.0% | -$16.6M+29.5% | -$23.6M-31.8% | -$17.9M+23.3% | -$23.3M+70.0% | -$77.6M | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$5.5M+73.6% | -$20.9M-41.4% | -$14.8M+30.8% | -$21.4M-39.6% | -$15.3M+25.1% | -$20.4M+72.6% | -$74.5M | N/A |
| EPS (Diluted) | $-0.82+73.7% | $-3.12-1318.2% | $-0.22 | N/A | $-2.29+25.4% | $-3.07-174.1% | $-1.12 | N/A |
GBIO Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $121.9M-32.1% | $179.4M-10.9% | $201.3M-12.9% | $231.2M-7.1% | $248.8M-6.2% | $265.3M-7.2% | $285.9M-23.7% | $374.8M |
| Current Assets | $93.5M-35.8% | $145.5M-11.9% | $165.1M-14.4% | $192.9M+0.9% | $191.3M-14.3% | $223.3M-1.6% | $226.9M-16.8% | $272.6M |
| Cash & Equivalents | $21.9M-55.3% | $49.1M-3.5% | $50.9M-33.3% | $76.3M+252.3% | $21.7M-24.0% | $28.5M-19.8% | $35.5M-46.5% | $66.4M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $391K+52.7% | $256K-81.6% | $1.4M+13.7% | $1.2M-44.7% | $2.2M+65.4% | $1.3M | N/A | $0 |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $71.3M-43.1% | $125.3M-2.1% | $128.0M-11.7% | $145.0M+0.5% | $144.3M-3.7% | $149.9M-2.6% | $153.9M-10.3% | $171.6M |
| Current Liabilities | $21.0M+8.6% | $19.4M-1.2% | $19.6M-44.1% | $35.1M+16.2% | $30.2M+0.2% | $30.1M+6.3% | $28.3M-29.1% | $39.9M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $50.6M-6.5% | $54.1M-26.2% | $73.3M-14.9% | $86.2M-17.5% | $104.4M-9.5% | $115.4M-12.6% | $132.0M-35.0% | $203.1M |
| Retained Earnings | -$744.3M-0.7% | -$738.8M-2.9% | -$717.8M-2.1% | -$703.0M-3.1% | -$681.7M-2.3% | -$666.4M-3.2% | -$645.9M-13.0% | -$571.4M |
GBIO Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$52.7M-213.0% | -$16.8M+40.7% | -$28.4M-79.7% | -$15.8M+19.3% | -$19.5M+9.2% | -$21.5M+32.1% | -$31.7M-26.9% | -$25.0M |
| Capital Expenditures | $0-100.0% | $459K+86.6% | $246K-34.9% | $378K+315.4% | $91K+550.0% | $14K-99.3% | $1.9M-58.1% | $4.6M |
| Free Cash Flow | -$52.7M-204.7% | -$17.3M+39.6% | -$28.6M-77.0% | -$16.2M+17.7% | -$19.6M+8.9% | -$21.5M+35.9% | -$33.6M-13.7% | -$29.6M |
| Investing Cash Flow | $25.5M+70.7% | $15.0M+405.6% | $3.0M-95.8% | $70.3M+453.1% | $12.7M+5.1% | $12.1M+2286.3% | -$553K+71.1% | -$1.9M |
| Financing Cash Flow | -$2K-102.5% | $80K+1242.9% | -$7K-104.9% | $144K+4900.0% | -$3K-101.3% | $234K+287.2% | -$125K-262.3% | $77K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
GBIO Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -420.8%+2574.7pp | -2995.6%-2805.2pp | -190.4%+372.3pp | -562.6%-325.9pp | -236.8%+333.0pp | -569.8%+1342.9pp | -1912.6% | N/A |
| Net Margin | -346.3%+2388.7pp | -2735.0%-2565.3pp | -169.7%+340.9pp | -510.6%-307.8pp | -202.7%+296.7pp | -499.4%+1337.0pp | -1836.4% | N/A |
| Return on Equity | -10.9%+27.7pp | -38.7%-18.5pp | -20.2%+4.6pp | -24.8%-10.1pp | -14.7%+3.0pp | -17.7%+38.8pp | -56.5% | N/A |
| Return on Assets | -4.5%+7.1pp | -11.7%-4.3pp | -7.3%+1.9pp | -9.3%-3.1pp | -6.2%+1.5pp | -7.7%+18.4pp | -26.1% | N/A |
| Current Ratio | 4.44-3.1 | 7.51-0.9 | 8.43+2.9 | 5.50-0.8 | 6.34-1.1 | 7.42-0.6 | 8.01+1.2 | 6.83 |
| Debt-to-Equity | 1.41-0.9 | 2.32+0.6 | 1.75+0.1 | 1.68+0.3 | 1.38+0.1 | 1.30+0.1 | 1.17+0.3 | 0.84 |
| FCF Margin | -3304.9%-1045.2pp | -2259.7%-1931.8pp | -327.9%+58.0pp | -385.9%-125.9pp | -260.0%+266.8pp | -526.7%+301.4pp | -828.2% | N/A |
Similar Companies
Frequently Asked Questions
What is Generation Bio Co.'s annual revenue?
Generation Bio Co. (GBIO) reported $19.9M in total revenue for fiscal year 2024. This represents a 236.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Generation Bio Co.'s revenue growing?
Generation Bio Co. (GBIO) revenue grew by 236.9% year-over-year, from $5.9M to $19.9M in fiscal year 2024.
Is Generation Bio Co. profitable?
No, Generation Bio Co. (GBIO) reported a net income of -$131.7M in fiscal year 2024, with a net profit margin of -661.9%.
What is Generation Bio Co.'s EBITDA?
Generation Bio Co. (GBIO) had EBITDA of -$137.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Generation Bio Co.'s operating margin?
Generation Bio Co. (GBIO) had an operating margin of -715.8% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Generation Bio Co.'s net profit margin?
Generation Bio Co. (GBIO) had a net profit margin of -661.9% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Generation Bio Co.'s return on equity (ROE)?
Generation Bio Co. (GBIO) has a return on equity of -152.7% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Generation Bio Co.'s free cash flow?
Generation Bio Co. (GBIO) generated -$91.0M in free cash flow during fiscal year 2024. This represents a -51.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Generation Bio Co.'s operating cash flow?
Generation Bio Co. (GBIO) generated -$88.6M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Generation Bio Co.'s total assets?
Generation Bio Co. (GBIO) had $231.2M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Generation Bio Co.'s capital expenditures?
Generation Bio Co. (GBIO) invested $2.4M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Generation Bio Co. spend on research and development?
Generation Bio Co. (GBIO) invested $61.3M in research and development during fiscal year 2024.
What is Generation Bio Co.'s current ratio?
Generation Bio Co. (GBIO) had a current ratio of 5.50 as of fiscal year 2024, which is generally considered healthy.
What is Generation Bio Co.'s debt-to-equity ratio?
Generation Bio Co. (GBIO) had a debt-to-equity ratio of 1.68 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Generation Bio Co.'s return on assets (ROA)?
Generation Bio Co. (GBIO) had a return on assets of -57.0% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Generation Bio Co.'s cash runway?
Based on fiscal year 2024 data, Generation Bio Co. (GBIO) had $76.3M in cash against an annual operating cash burn of $88.6M. This gives an estimated cash runway of approximately 10 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Generation Bio Co.'s Altman Z-Score?
Generation Bio Co. (GBIO) has an Altman Z-Score of -5.24, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Generation Bio Co.'s Piotroski F-Score?
Generation Bio Co. (GBIO) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Generation Bio Co.'s earnings high quality?
Generation Bio Co. (GBIO) has an earnings quality ratio of 0.67x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Generation Bio Co.?
Generation Bio Co. (GBIO) scores 45 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.